Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 8/20 | 0.47 |
| ▸ | MIF | P14174 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | ATM | Q13315 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | XBP1 | P17861 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | LY96 | Q9Y6Y9 | 1/20 | 0.40 |
| ▸ | IDH1 | O75874 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16264022 | 0.78 | ALDH1A1 (0.66) | MAOBALDH1A1MAPTATMHPGD | |
| SCHEMBL16264023 | 0.77 | MAOB (0.67) | MAOBMIFALDH1A1MAPTATM | |
| SCHEMBL17547649 | 0.77 | MAOB (0.50) | MAOBMIF | |
| SCHEMBL17547642 | 0.73 | MAOB (0.67) | MAOBMIFALDH1A1MAPTATM | |
| SCHEMBL17536657 | 0.73 | MAOB (0.67) | MAOBMIFALDH1A1MAPTATM | |
| SCHEMBL17547648 | 0.73 | MAPT (0.61) | MAOBALDH1A1MAPTHPGDMAPK1 | |
| SCHEMBL17547651 | 0.73 | TUBB1 (0.59) | MAOBALDH1A1MAPTATMHPGD | |
| SCHEMBL17547652 | 0.73 | MAPT (0.58) | MAOBMIFALDH1A1MAPTATM | |
| SCHEMBL17547645 | 0.72 | MAOB (0.56) | MAOBALDH1A1MAPTATMHPGD | |
| SCHEMBL17547646 | 0.71 | MAOB (0.58) | MAOBALDH1A1MAPTATMHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11707445-B2 | Composition for blocking angiogenesis | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2023-07-25 | — | — | US | disclosed |
| US-11707445-B2 | Composition for blocking angiogenesis | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2023-07-25 | — | — | US | disclosed |
| US-20210228538-A1 | COMPOSITION FOR BLOCKING ANGIOGENESIS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2021-07-29 | — | — | US | disclosed |
| US-10738024-B2 | Compounds for treatment of angiogenesis-mediated diseases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2020-08-11 | — | — | US | disclosed |
| US-10238627-B2 | Compounds for treatment of angiogenesis-mediated diseases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2019-03-26 | — | — | US | disclosed |
| US-20180177758-A1 | COMPOUNDS FOR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2018-06-28 | — | — | US | disclosed |
| US-20180177758-A1 | COMPOUNDS FOR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2018-06-28 | — | — | US | disclosed |
| WO-2017091473-A1 | COMPOSITION FOR BLOCKING ANGIOGENESIS | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) | 2017-06-01 | — | — | WO | disclosed |
| US-20160060241-A1 | COMPOUNDS FOR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES | GACHON UNIVERSITY OF INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2016-03-03 | — | — | US | disclosed |
| US-20160060241-A1 | COMPOUNDS FOR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES | GACHON UNIVERSITY OF INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2016-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11707445-B2 | Composition for blocking angiogenesis | FLT4, KDR, VEGFA | MAOB 2971/4885MIF 1804/4885ALDH1A1 3065/4885 |
| US-10738024-B2 | Compounds for treatment of angiogenesis-mediated diseases | KDR, TEK, VEGFA | MAOB 1469/4885MIF 2924/4885ALDH1A1 1077/4885 |
| US-20210228538-A1 | COMPOSITION FOR BLOCKING ANGIOGENESIS | FLT4, KDR, VEGFA | MAOB 2971/4885MIF 1804/4885ALDH1A1 3065/4885 |
| US-20180177758-A1 | COMPOUNDS FOR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES | KDR, TEK, VEGFA | MAOB 1469/4885MIF 2924/4885ALDH1A1 1077/4885 |
| US-20160060241-A1 | COMPOUNDS FOR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES | KDR, TEK, VEGFA | MAOB 1469/4885MIF 2924/4885ALDH1A1 1077/4885 |
| US-10238627-B2 | Compounds for treatment of angiogenesis-mediated diseases | KDR, TEK, VEGFA | MAOB 1469/4885MIF 2924/4885ALDH1A1 1077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.